Quick Answer
Your insurer labeled your treatment 'experimental' or 'investigational.' Learn how to appeal using FDA approvals, NCCN guidelines, and clinical trial protections. AppealArmor drafts an appeal letter for this denial from your denial letter — free, no account required.
Last updated: 2026-06-30 · Source: AppealArmor · About the authors
Experimental Treatment Help
Insurers use the "experimental" label to deny treatments that are FDA-approved, listed in the NCCN Compendium, or covered by Medicare. When the evidence is on your side, a properly built appeal — especially through external independent review — can change the outcome.
Generate Your Experimental Treatment Appeal — FreeNo account required. Encrypted; your identifiers are removed before drafting.
Free, always. No account. You review every word before you send it — and we never send anything to your insurer. You do.
Got a denial letter? Upload a PDF or a photo of it, check the details we read from it, and we’ll draft your appeal.
Start my free appeal →Free, always. No account. You review every word before you send it — and we never send anything to your insurer. You do.
The "experimental" or "investigational" label is one of the most aggressive denial tactics in the insurance industry. Insurers apply this designation to avoid covering treatments that may be perfectly well-established in clinical practice but have not received FDA approval for the specific indication or are being used in ways the insurer considers outside their internal coverage criteria.
Here is the critical distinction: FDA approval status and insurance coverage criteria are not the same thing as accepted medical practice. Many treatments used daily by physicians nationwide -- and even covered by Medicare -- are labeled "experimental" by commercial insurers to avoid payment.
Sources: NCCN, CMS external review data, peer-reviewed oncology literature
Upload the denial that labels your treatment as experimental or investigational. AppealArmor reads the denial reason, the service and the appeal deadline, and you confirm every detail before anything is written.
For a drug, AppealArmor looks up the FDA label on openFDA and can quote it. NCCN listings, coverage determinations and published studies have to come from your doctor.
Your packet is the appeal letter (Word and PDF) and a Next Steps sheet: where to send it, your deadline as your letter states it, who to copy, and who to contact if it is denied again. For drugs, the letter can quote the FDA label. When your plan has an external independent review, the Next Steps sheet says who to contact for it -- which is especially important for experimental treatment denials.
The gold standard for oncology treatments. CMS and most major insurers recognize NCCN listings as evidence of accepted medical practice. Category 1 (high-level evidence) and Category 2A (uniform consensus) listings are extremely strong in appeals. Federal law requires Medicare and many state laws require commercial insurers to cover NCCN-listed treatments.
If Medicare covers the treatment through a National Coverage Determination or Local Coverage Determination, the insurer's "experimental" label is significantly weakened. CMS conducts rigorous evidence review before issuing coverage determinations.
The ACA prohibits plans from denying routine patient costs associated with approved clinical trials. Plans cannot drop coverage, increase premiums, or deny routine services because you are participating in a qualified clinical trial.
Over 35 states have laws requiring coverage of off-label drug uses when supported by recognized compendiums (NCCN, AHFS-DI, Clinical Pharmacology). If your denied treatment is an FDA-approved drug used for an off-label indication supported by a recognized compendium, state law may mandate coverage.
In insurance terms, it means the insurer has determined the treatment lacks sufficient evidence of safety and effectiveness for your specific condition. However, this determination is based on the insurer's own criteria, which may be more restrictive than what the broader medical community accepts. A treatment that is standard care at major cancer centers can still be labeled "experimental" by an insurer.
Likely not. If a drug is FDA-approved for any indication and is being used off-label with support from recognized compendiums (NCCN, AHFS-DI, Clinical Pharmacology), federal and state laws generally require coverage. The insurer's "experimental" designation does not override the clinical evidence or compendium listings that support the treatment.
Yes. Under the ACA (Section 2709), plans must cover routine patient costs -- office visits, labs, imaging, hospital stays -- when you participate in an approved clinical trial. The trial sponsor covers the investigational item itself. Your plan cannot penalize you for trial participation.
The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium is the most widely recognized reference for cancer treatment coverage decisions. CMS uses it as a standard, and it is recognized by law in most states. If your cancer treatment is listed in the NCCN Compendium, this is powerful evidence against an "experimental" denial.
Internal appeals succeed 33-52% of the time. When the treatment is supported by NCCN or CMS coverage determinations, external independent reviews overturn denials more than 60% of the time. The external reviewer is typically a physician with relevant specialty expertise who independently evaluates the clinical evidence.
Upload your denial letter — a PDF or a photo of the paper letter works. You check every detail we read from it, then we draft the appeal and quote the federal appeal rules for your type of plan. You read it, change anything you want, and send it yourself.
Start my free appeal →Free, always. No account. You review every word before you send it — and we never send anything to your insurer. You do.
